Inozyme Pharma Inc (INZY) is higher by 32.61% in a Week, Should You Buy?

by InvestorsObserver, Benzinga Columnist
March 27, 2023 10:55 AM | 17 seconds read |
A rating of 95 puts Inozyme Pharma Inc (INZY) near the top of the Biotechnology industry according to InvestorsObserver. Inozyme Pharma Inc's score of 95 means it scores higher than 95% of stocks in the industry. Inozyme Pharma Inc also received an overall rating of 81, putting it above 81% of all stocks. Biotechnology is
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!